SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-022596
Filing Date
2022-11-07
Accepted
2022-11-07 16:07:09
Documents
65
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cyt-20220930.htm   iXBRL 10-Q 2421705
2 EX-31.1 cyt-ex31_1.htm EX-31.1 21275
3 EX-31.2 cyt-ex31_2.htm EX-31.2 21251
4 EX-32.1 cyt-ex32_1.htm EX-32.1 12376
5 EX-32.2 cyt-ex32_2.htm EX-32.2 12362
  Complete submission text file 0000950170-22-022596.txt   7052317

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cyt-20220930_def.xml EX-101.DEF 134593
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cyt-20220930_pre.xml EX-101.PRE 259180
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cyt-20220930.xsd EX-101.SCH 42039
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cyt-20220930_lab.xml EX-101.LAB 362337
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cyt-20220930_cal.xml EX-101.CAL 41285
59 EXTRACTED XBRL INSTANCE DOCUMENT cyt-20220930_htm.xml XML 1134222
Mailing Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421
Business Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421 857-285-4140
Cyteir Therapeutics, Inc. (Filer) CIK: 0001662244 (see all company filings)

IRS No.: 455429901 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40499 | Film No.: 221365447
SIC: 2834 Pharmaceutical Preparations